Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration

References

• Rosenfeld PJ, Brown DM, Heier JS; MARINA Study Group, et al.. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431. doi:10.1056/NEJMoa054481
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M; ANCHOR Study Group, et al.. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444. doi:10.1056/NEJMoa062655
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V; VIEW 1 and VIEW 2 Study Groups, et al.. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–2548. doi:10.1016/j.ophtha.2012.09.006
   PubMed Web of Science ®Google Scholar
• Zandi S, Weisskopf F, Garweg JG, et al. Pre-existing RPE atrophy and defects in the external limiting membrane predict early poor visual response to ranibizumab in neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2017;48:326–332. doi:10.3928/23258160-20170329-07
   Web of Science ®Google Scholar
• Sadda SR, Tuomi LL, Ding B, Fung AE, Hopkins JJ. Macular atrophy in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology. 2018;125:878–886. doi:10.1016/j.ophtha.2017.12.026
   PubMed Web of Science ®Google Scholar
• Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119:1175–1183. doi:10.1016/j.ophtha.2011.12.016
   PubMed Web of Science ®Google Scholar
• Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–2299. doi:10.1016/j.ophtha.2013.03.046
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, et al.. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–1398. doi:10.1016/j.ophtha.2012.03.053
   PubMed Web of Science ®Google Scholar
• Richard G, Monés J, Wolf S, et al. Scheduled versus pro re nata dosing in the VIEW trials. Ophthalmology. 2015;122:2497–2503. doi:10.1016/j.ophtha.2015.08.014
   Web of Science ®Google Scholar
• Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220–226. doi:10.1136/bjophthalmol-2014-305327
   PubMed Web of Science ®Google Scholar
• Garweg JG, Zirpel JJ, Gerhardt C, Pfister IB. The fate of eyes with wet AMD beyond four years of anti-VEGF therapy. Graefes Arch Clin Exp Ophthalmol. 2018;256:823–831. doi:10.1007/s00417-018-3907-y
   PubMed Web of Science ®Google Scholar
• Ehlken C, Helms M, Böhringer D, Agostini HT, Stahl A. Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol. 2017;12:13–20. doi:10.2147/OPTH.S151611
   PubMed Web of Science ®Google Scholar
• Holz FG, Tadayoni R, Beatty S, et al. Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol. 2016;100:1623–1628. doi:10.1136/bjophthalmol-2015-308166
   PubMed Web of Science ®Google Scholar
• Holz FG, Tadayoni R, Beatty S, et al. Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study. Eye (Lond). 2016;30:1063–1071. doi:10.1038/eye.2016.90
   PubMed Web of Science ®Google Scholar
• Droege KM, Caramoy A, Kersten A, et al. Patient preference of ranibizumab treatment regimen for neovascular age-related macular degeneration - monthly injections versus pro re nata. Graefes Arch Clin Exp Ophthalmol. 2014;252:31–34. doi:10.1007/s00417-013-2412-6
   Web of Science ®Google Scholar
• Ba J, Peng RS, Xu D, et al. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Drug Des Devel Ther. 2015;9:5397–5405. doi:10.2147/DDDT.S86269
   PubMed Web of Science ®Google Scholar
• Szabo SM, Hedegaard M, Chan K, et al. Ranibizumab vs. aflibercept for wet age-related macular degeneration: network meta-analysis to understand the value of reduced frequency dosing. Curr Med Res Opin. 2015;31:2031–2042. doi:10.1185/03007995.2015.1084909
   PubMed Web of Science ®Google Scholar
• Stewart MW. Individualized treatment of neovascular age-related macular degeneration: what are patients gaining? Or losing? J Clin Med. 2015;4:1079–1101. doi:10.3390/jcm4051079
   PubMed Web of Science ®Google Scholar
• Garweg JG, Niderprim SA, Russ HM, Pfister IB. Comparison of strategies of treatment with ranibizumab in newly-diagnosed cases of neovascular age-related macular degeneration. J Ocul Pharmacol Ther. 2017;33:773–778. doi:10.1089/jop.2017.0006
   Web of Science ®Google Scholar
• Garweg JG, Gerhardt C, Kodjikian L, Pfister IB. Real-life experience with aflibercept and ranibizumab in the treatment of newly diagnosed neovascular age-related macular degeneration over 24 months. J Ocul Pharmacol Ther. 2017;33:567–572. doi:10.1089/jop.2017.0031
   Web of Science ®Google Scholar
• Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239–248. doi:10.1016/j.ajo.2007.10.004
   PubMed Web of Science ®Google Scholar
• Kim LN, Mehta H, Barthelmes D, Nguyen V, Gillies MC. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina. 2016;36:1418–1431. doi:10.1097/IAE.0000000000001142
   PubMed Web of Science ®Google Scholar
• Nguyen CL, Oh LJ, Wong E, Wei J, Chilov M. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. BMC Ophthalmol. 2018;18:130. doi:10.1186/s12886-018-0785-3
   PubMed Web of Science ®Google Scholar
• Hernandez L, Lanitis T, Cele C, Toro-Diaz H, Gibson A, Kuznik A. Intravitreal aflibercept versus ranibizumab for wet age-related macular degeneration: a cost-effectiveness analysis. J Manag Care Spec Pharm. 2018;24:608–616. doi:10.18553/jmcp.2018.24.7.608
   Web of Science ®Google Scholar
• van Asten F, Michels CTJ, Hoyng CB, et al. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective. PLoS One. 2018;13:e0197670. doi:10.1371/journal.pone.0197670
   PubMed Web of Science ®Google Scholar
• Schmid MK, Reich O, Faes L, et al. Comparison of outcomes and costs of ranibizumab and aflibercept treatment in real-life. PLoS One. 2015;10:e0135050. doi:10.1371/journal.pone.0135050
   Web of Science ®Google Scholar
• Martin DF. Evolution of intravitreal therapy for retinal diseases-from CMV to CNV: the LXXIV Edward Jackson Memorial Lecture. Am J Ophthalmol. 2018;191:xli–lviii. doi:10.1016/j.ajo.2017.12.019
   Web of Science ®Google Scholar
• Hussain RM, Hariprasad SM, Ciulla TA. Treatment burden in neovascular AMD:visual acuity outcomes are associated with anti-VEGF injection frequency. Ophthalmic Surg Lasers Imaging Retina. 2017;48:780–784. doi:10.3928/23258160-20170928-01
   PubMed Web of Science ®Google Scholar
• Saxena N, George PP, Hoon HB, Han LT, Onn YS. Burden of wet age-related macular degeneration and its economic implications in Singapore in the year 2030. Ophthalmic Epidemiol. 2016;23:232–237. doi:10.1080/09286586.2016.1193617
   PubMed Web of Science ®Google Scholar
• Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol. 2015;160(725–731.e1). doi:10.1016/j.ajo.2015.06.023
   Web of Science ®Google Scholar
• Mantel I. [Age-related macular degeneration – a challenge for public health care]. Ther Umsch. 2016;73:79–83. doi:10.1024/0040-5930/a000760
   Google Scholar
• Neves Cardoso P, Pinheiro AF, Meira J, et al. Switch to aflibercept in the treatment of neovascular AMD: long-term results. J Ophthalmol. 2017;2017:6835782. doi:10.1155/2017/6835782
   PubMed Web of Science ®Google Scholar
• Eleftheriadou M, Gemenetzi M, Lukic M, et al. Three-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: evidence from a clinical setting. Ophthalmol Ther. 2018;7:361–368. doi:10.1007/s40123-018-0139-5
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Thorne JE, Ho AC, et al. Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a Report by the American Academy of Ophthalmology. Ophthalmology. 2019;126:55–63. doi:10.1016/j.ophtha.2018.07.028
   PubMed Web of Science ®Google Scholar
• Traine PG, Pfister IB, Zandi S, Spindler J, Garweg JG. Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a „treat-and-extend“ regimen. Ophthalmol Retina. 2019;3:393–399. doi:10.1016/j.oret.2019.01.018
   PubMedGoogle Scholar
• Zhang X, Lai TYY. Baseline predictors of visual acuity outcome in patients with wet age-related macular degeneration. Biomed Res Int. 2018;2018:9640131. doi:10.1155/2018/9640131
   PubMed Web of Science ®Google Scholar
• Ashraf M, Souka A, Adelman RA. Age-related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmol. 2018;96:120–133. doi:10.1111/aos.13565
   PubMed Web of Science ®Google Scholar
• Tsilimbaris MK, López-Gálvez MI, Gallego-Pinazo R, Margaron P, Lambrou GN. Epidemiological and clinical baseline characteristics as predictive biomarkers of response to anti-VEGF treatment in patients with neovascular AMD. J Ophthalmol. 2016;2016:4367631. doi:10.1155/2016/4367631
   Web of Science ®Google Scholar
• Ying GS, Maguire MG, Daniel E; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, et al.. Association of baseline characteristics and early vision response with 2-year vision outcomes in the comparison of AMD Treatments Trials (CATT). Ophthalmology. 2015;122(2523–31.e1). doi:10.1016/j.ophtha.2015.08.015
   Web of Science ®Google Scholar
• Kwon YH, Lee DK, Kim HE, Kwon OW. Predictive findings of visual outcome in spectral domain optical coherence tomography after ranibizumab treatment in age-related macular degeneration. Korean J Ophthalmol. 2014;28:386–392. doi:10.3341/kjo.2014.28.5.386
   Google Scholar
• Garweg JG. Atrophy of the macula in the context of its wet, age-related degeneration: an inescapable consequence of anti-VEGF therapy? Ophthalmologe. 2016;113:1036–1045. doi:10.1007/s00347-016-0306-9
   PubMed Web of Science ®Google Scholar
• Munk MR, Ceklic L, Ebneter A, Huf W, Wolf S, Zinkernagel MS. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol. 2016;94:e757–e764. doi:10.1111/aos.13157
   PubMed Web of Science ®Google Scholar
• Amoaku WM, Chakravarthy U, Gale R, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015;29:721–731. doi:10.1038/eye.2015.48
   PubMed Web of Science ®Google Scholar
• Dugel PU, Jaffe GJ, Sallstig P, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124:1296–1304. doi:10.1016/j.ophtha.2017.03.057
   PubMed Web of Science ®Google Scholar
• Barthelmes D, Nguyen V, Daien V; Fight Retinal Blindness Study Group, et al.. Two year outcomes of “Treat and extend” intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration. Retina. 2018;38:20–28. doi:10.1097/IAE.0000000000001496
   PubMed Web of Science ®Google Scholar
• Regillo CD, Busbee BG, Ho AC, Ding B, Haskova Z. Baseline predictors of 12-month treatment response to ranibizumab in patients with wet age-related macular degeneration. Am J Ophthalmol. 2015;160(5):1014–1023.e2. doi:10.1016/j.ajo.2015.07.034
   Web of Science ®Google Scholar
• Finger RP, Wickremasinghe SS, Baird PN, Guymer RH. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. Surv Ophthalmol. 2014;59:1–18. doi:10.1016/j.survophthal.2013.03.009
   PubMed Web of Science ®Google Scholar
• Sagiv O, Zloto O, Moroz I, Moisseiev J. Different clinical courses on long-term follow-up of age-related macular degeneration patients treated with intravitreal anti-vascular endothelial growth factor injections. Ophthalmologica. 2017;238:217–225. doi:10.1159/000479437
   Web of Science ®Google Scholar
• Nguyen V, Daien V, Guymer R; Fight Retinal Blindness! Study Group, et al.. Projection of long-term visual acuity outcomes based on initial treatment response in neovascular age-related macular degeneration. Ophthalmology. 2019;126:64–74. doi:10.1016/j.ophtha.2018.08.023
   PubMed Web of Science ®Google Scholar
• Gillies MC, Nguyen V, Daien V, Arnold JJ, Morlet N, Barthelmes D. Twelve-month outcomes of ranibizumab vs. Aflibercept for neovascular age-related macular degeneration: data from an observational study. Ophthalmology. 2016;123:2545–2553. doi:10.1016/j.ophtha.2016.08.016
   Web of Science ®Google Scholar
• Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193–201. doi:10.1016/j.ophtha.2013.08.011
   Google Scholar
• Wykoff CC, Clark WL, Nielsen JS, Brill JV, Greene LS, Heggen CL. Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. J Manag Care Spec Pharm. 2018;24(2–a Suppl):S3–S15. doi:10.18553/jmcp.2018.24.2-a.s3
   PubMed Web of Science ®Google Scholar
• Pron G. Optical coherence tomography monitoring strategies for A-VEGF-treated age-related macular degeneration: an evidence-based analysis. Ont Health Technol Assess Ser. 2014;14:1–64.
   Google Scholar
• Silva R, Cachulo ML, Fonseca P, et al. Age-related macular degeneration and risk factors for the development of choroidal neovascularisation in the fellow eye: a 3-year follow-up study. Ophthalmologica. 2011;226:110–118. doi:10.1159/000329473
   Web of Science ®Google Scholar
• Mann SS, Rutishauser-Arnold Y, Peto T, et al. The symmetry of phenotype between eyes of patients with early and late bilateral age-related macular degeneration (AMD). Graefes Arch Clin Exp Ophthalmol. 2011;249:209–214. doi:10.1007/s00417-010-1483-x
   Web of Science ®Google Scholar
• Chevreaud O, Semoun O, Blanco-Garavito R, et al. Visual acuity at presentation in the second eye versus first eye in patients with exudative age-related macular degeneration. Eur J Ophthalmol. 2016;26:44–47. doi:10.5301/ejo.5000649
   Web of Science ®Google Scholar
• Lee AY, Lee CS, Butt T; UK AMD EMR Users Group, et al.. UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12. Br J Ophthalmol. 2015;99:1045–1050. doi:10.1136/bjophthalmol-2014-306229
   Web of Science ®Google Scholar
• Li J, Xu J, Chen Y, Zhang J, Cao Y, Lu P. Efficacy comparison of intravitreal anti-VEGF therapy for three subtypes of neovascular age-related macular degeneration: a systematic review and meta-analysis. J Ophthalmol. 2018;2018:1425707. doi:10.1155/2018/1425707
   Web of Science ®Google Scholar
• Muftuoglu IK, Tsai FF, Gaber R, Alam M, Meshi A, Freeman WR. High-frequency aflibercept injections in persistent neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2017;255:709–717. doi:10.1007/s00417-016-3547-z
   Web of Science ®Google Scholar
• Abdelfattah NS, Zhang H, Boyer DS, et al. Drusen volume as a predictor of disease progression in patients with late age-related macular degeneration in the fellow eye. Invest Ophthalmol Vis Sci. 2016;57:1839–1846. doi:10.1167/iovs.15-18572
   Web of Science ®Google Scholar
• Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol. 2014;158:532–536. doi:10.1016/j.ajo.2014.05.025
   PubMed Web of Science ®Google Scholar
• Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF trap. Br J Ophthalmol. 2008;92:667–668. doi:10.1136/bjo.2007.134874
   PubMed Web of Science ®Google Scholar
• Muether PS, Hoerster R, Hermann MM, Kirchhof B, Fauser S. Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2013;251:453–458. doi:10.1007/s00417-012-2038-0
   Web of Science ®Google Scholar
• Rasmussen A, Brandi S, Fuchs J, et al. Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration. Acta Ophthalmol. 2015;93:616–620. doi:10.1111/aos.12781
   PubMed Web of Science ®Google Scholar
• Cazet-Supervielle A, Gozlan J, Cabasson S, Boissonnot M, Manic H, Leveziel N. Intravitreal ranibizumab in daily clinical practice for age-related macular degeneration: treatment of exudative age-related macular degeneration in real life. Ophthalmologica. 2015;234:26–32. doi:10.1159/000430470
   Web of Science ®Google Scholar
• Ohji M, Okada AA, Takahashi K, Kobayashi M, Terano Y. Two Different Treat and Extend Dosing Regimens of Intravitreal Afibercept for wAMD in Japanese Patients: 52 Week Results of the ALTAIR Study. Barcelona: Euretina Meeting; 2017.
   Google Scholar
• Ohji M, Okada AA, Takahashi K, Kobayashi M, Terano Y. Two Different Treat-And-Extend Dosing Regimens of Intravitreal Aflibercept in Japanese Patients with Wet Age-Related Macular Degeneration: 96-Week Results of the ALTAIR Study. Vienna: Euretina Meeting; 2018.
   Google Scholar